UNASSIGNED: 293 Background: There is a variety of chemotherapy regimens used as first-line treatment in advanced @entity1149 ( @entity1149 ). Few studies have used real-world data to compare the clinical outcomes associated with different chemotherapy combinations. The study objective was to compare overall survival between chemotherapy regimens used for @entity1 with advanced @entity1149 in an integrated healthcare system. METHODS: This retrospective cohort analysis included @entity1 age 18 or older from Northern and Southern California Kaiser Permanente with a diagnosis of Stage IIIB/IV @entity1149 identified in the @entity5 registry. First chemotherapy date occurred from January 2008 through September 2012 with at least 6 months of follow up to March 31, 2013. Overall survival was measured as the number of months from initial chemotherapy until death, end of enrollment or March 31, 2013. Chemotherapy regimens were categorized into five mutually exclusive groups: pemetrexed-based, pemetrexed + bevacizumab, bevacizumab-based, @entity902 doublets and singlets. Survival was compared between the five groups using Cox proportional hazard models, adjusting for age, gender, race, region, stage, histology, days from diagnosis to initial chemotherapy and Diagnostic Cost Group (DxCG) risk score. The analysis was performed for all age groups and by age over and under 65. RESULTS: Among 1,989 adults, those that received singlet chemotherapy were at significantly increased risk of mortality compared to doublets (HR 1.23; 95% CI 1.02-1.49). @entity1 younger than 65 who had received pemetrexed + bevacizumab regimens were at significantly reduced risk of mortality (HR 0.58; 95% CI 0.35-0.95) when compared to @entity902 doublets. Among @entity1 over 65, there were no significant differences in survival between the chemotherapy regimens. CONCLUSIONS: Adult @entity1 with advanced @entity1149 who are younger than 65 years old have improved survival after receiving pemetrexed + bevacizumab chemotherapy regimens compared to @entity902 doublet regimens. No survival differences were found between regimens in @entity1 over the age of 65.

Comparative effectiveness of first-line chemotherapies in advanced XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer'] @entity902 :: ('MESH:D010984', 'Chemical') :: ['platinum'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']
@entity1149 :: (MESH:D002289,Disease) :: ['non-small cell lung cancer']
